| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 13, 2005
Accepted on May 8, 2006
Laboratory of Clinical Genomics, National Institute of Child Health and Human Development, and Center for Molecular Modeling, Division of Computational Bioscience, Center for Information Technology, National Institutes of Health, Bethesda, MD 20892; Department of Pediatrics, Stanford University, Stanford, CA 94305, U.S.A.; Department of Pediatrics, Georgetown University, Washington, DC 20007
* To whom correspondence should be addressed. E-mail: chanwy{at}mail.nih.gov.
A novel heterozygous mutation A340T leading to the substitution of Phe for the conserved amino acid Ile-114 was identified by nucleotide sequencing of the human LH/chorionic gonadotropin receptor (hLHR) of a patient with Leydig Cell Hypoplasia (LCH). This mutation is located in the third leucine-rich repeat (LRR) in the ectodomain of the hLHR. In vitro expression studies demonstrated that this mutation results in reduced ligand binding and signal transduction of the receptor. Studies of hLHR constructs where various amino acids were substituted for the conserved Ile-114 showed that receptor activity is sensitive to changes in size, shape, and charge of the side chain. A homology model of the wild-type hLHR ectodomain was made, illustrating the packing of conserved hydrophobic side chains in the protein core. Substitution of Ile-114 by Phe might disrupt intermolecular contacts between hormone and receptor. This mutation might also affect an LHR-dimer interaction. Thus, the I114F mutation reduces ligand binding and signal transduction by the hLHR, and it is partially responsible for LCH in the patient.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |